Classical Hodgkin Lymphoma clinical trials

Explore recruiting classical hodgkin lymphoma clinical trials.

Recruiting classical hodgkin lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Classical Hodgkin Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)

France, Poland, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Spain, Czechia, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

INDIE: Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Denmark, Hungary, Italy, Belgium, Spain, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Italy, Denmark, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PREFer: Phase II trial of anti-PD-1 antibody treatment and radiotherapy in early-stage favorable classic Hodgkin lymphoma

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Classical Hodgkin Lymphoma trials by city

Classical Hodgkin Lymphoma in Toronto Classical Hodgkin Lymphoma in Vancouver Classical Hodgkin Lymphoma in Montreal Classical Hodgkin Lymphoma in Calgary Classical Hodgkin Lymphoma in Edmonton Classical Hodgkin Lymphoma in Ottawa Classical Hodgkin Lymphoma in Winnipeg Classical Hodgkin Lymphoma in Quebec City Classical Hodgkin Lymphoma in Hamilton Classical Hodgkin Lymphoma in Kitchener Classical Hodgkin Lymphoma in London Classical Hodgkin Lymphoma in Halifax Classical Hodgkin Lymphoma in New York Classical Hodgkin Lymphoma in Los Angeles Classical Hodgkin Lymphoma in Chicago Classical Hodgkin Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease